Live Webinar Process Validation - Statistical Process Control

01:00 PM EDT | 10:00 AM PDT | 12:00 PM CDT Duration 90 Minutes

Webinar Includes : All the training handouts , certificate ,Q/A and 90 mins Live Webinar

"Hear By JERRY DALFORS is considered an expert in most all aspects of the biopharmaceutical and medical device industry and has trained many FDA field inspectors on a variety of topics. "

To gain a current comprehension of the new PV Guidelines

Description

Process knowledge and understanding is the basis for establishing an approach to process control and related instruction sets in the Batch Record for each critical step of the process operation and process results. Strategies for process control and operator activities can be designed to reduce variation, adjust to variation during manufacturing and reduced possibility for operator error. Statistical Process Control

Batch Records are to be configured to provide documented evidence for potential quality impact with implemented risk remediation and objective evidence with which each step has been executed as instructed in the Batch Record. The Batch Record Review document is to be formatted to ensure execution and documentation of each critical element of the process as per the industry standards for GDP.

The ultimate goal of Process Validation is to ensure continual assurance that the process once validated (PQ now PPQ) and submitted for FDA/EU approval remains in a state of control by detecting unplanned departures from the initially proven acceptable process to meet cGMP requirements. By conducting a specifically designed monitoring system and then as required by regulatory requirements that a statistician or person with adequate training in statistical process control to monitory, sample and analyze the quality attributes of each critical step of a process and also compare batch to batch consistency using the statistical analysis using the appropriate model.

Why Should you Attend:

To gain a current comprehension of the new PV Guidelines and the determination of how to do the required Statistical Monitoring and Data Analysis to prove the process is consistent and to avoid situations that could cause 483s, Warning Letters and Consent Decrees as well as gaining the capability of avoiding rework and recall expenses

Areas Covered

Process knowledge and understanding is the basis for establishing an approach to process control and related instruction sets in the Batch Record for each unit operation and the process overall. Strategies for process control and operator activities can be designed to reduce input variation, adjust for input variation during manufacturing and reduced possibility for operator error, as well as an overall blend to manage critical process parameters (CPPs).

Statistical Tracking (database entry and design) along with Annual Report Generation. Variation can also be detected by the timely assessment of defect complaints, out-of-specification findings, process deviation reports, process yield variations, batch records, incoming raw material records, and adverse event reports.

Production line operators and quality unit staff should be encouraged to provide feedback on process performance. We recommend that the quality unit meet periodically with production staff to evaluate data, discuss possible trends or undesirable process variation, and coordinate any correction or follow-up actions by production.

To understand the commercial process sufficiently, the manufacturer will need to consider the effects of scale. However, it is not typically necessary to explore the entire operating range at commercial scale if assurance can be provided by process design data. Previous credible experience with sufficiently similar products and processes can also be helpful. In addition, we strongly recommend firms employ objective measures (e.g., statistical metrics) wherever feasible and meaningful to achieve adequate assurance.

The goal of the third validation stage is continuous assurance that the process remains in a state of control (the validated state) during commercial manufacture. A system or systems for detecting unplanned departures from the process as designed is essential to accomplish this goal.

Adherence to the CGMP and GDP requirements, specifically, the collection and evaluation of information and data about the performance of the process, will allow detection of undesired process variability. Evaluating the performance of the process identifies problems and determines whether action must be taken to correct, anticipate, and prevent problems so that the process remains in control (§ 211.180(e)).

An ongoing program to collect and analyze product and process data that relate to product quality must be established (§ 211.180(e)). The data collected should include relevant process trends and quality of incoming materials or components, in-process material, and finished products. The data should be statistically trended and reviewed by trained personnel. The information collected should verify that the quality attributes are being appropriately controlled throughout the process.

FDA recommends that a statistician or person with adequate training in statistical process control techniques develop the data collection plan, statistical methods and procedures used in measuring and evaluating process stability and capability.

The old Process Validation or PQ (process qualification) was originally set-up in the pharmaceutical, not biotech or biopharmaceutical, using three runs with all variables being run at the target (center of the limits or range values). When biotech and biologics grew to such a large component of the industry, coincidental process variables still within limits began to introduce product failures which is why the FDA has added the phraseology about "sound science and the overall level of product and process understanding as well as demonstrable control" – i.e. Sound Scientific Rational (SSR).

Who will Benefit

--    Manufacturing Operations,
--    Formulation, Engineering,
--    QA/QC,
--    Product and Process Development,
--    Regulatory Affairs,
--    Research and Development,
--    Sterility Assurance,
--    Technical Operations and
--    Validation Professionals
--    FDA inspectors
--    Internal auditors.

Industries who can attend

This 90-minute online course is intended for professionals in the Medical Device, Biotechnology,Pharmaceutical Industry. Although not presently stated in the draft , the same guide could be used by FDA Regulated Industries personnel.


Speaker Profile

JERRY DALFORS

Mr. Jerry Dalfors has extensive (40+ years) of business administration, consultative, technical and managerial experience in the development and manufacture of highly regulated biopharmaceutical products including injectables, biologics, medical devices and oral dosages. He has held permanent employee, temporary employee and company representative management positions with a multitude of the major pharmaceutical and biotechnology companies in the US. He has worked with or assisted more than two dozen companies with the establishment of controlled document/quality systems, FDA briefing and submittal documents, project management of several multimillion dollar projects including design, start-up and validation to assure fast track FDA approval by maintaining strict regulatory compliance during all phases of engineering, construction, commissioning and validation, and has written numerous submission documents for product, process and facility approval/licensing which also required the development of quality systems which included customer complaint management, deviation management, CAPA and associated site wide employee training. Each of his projects have been received and accepted by the FDA and other regulatory agencies.

Jerry is considered an expert in most all aspects of the biopharmaceutical and medical device industry and has trained many FDA field inspectors on a variety of topics. None of his work has ever received a 483 but has corrected and prevented many along with Warning Letter remediation as well as reducing costs to make companies more profitable.

Back to Top